Sirio Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Sirio Pharma has a total shareholder equity of CN¥2.6B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 46.1%. Its total assets and total liabilities are CN¥5.3B and CN¥2.7B respectively. Sirio Pharma's EBIT is CN¥438.1M making its interest coverage ratio 4.4. It has cash and short-term investments of CN¥637.4M.
Key information
46.1%
Debt to equity ratio
CN¥1.19b
Debt
| Interest coverage ratio | 4.4x |
| Cash | CN¥637.40m |
| Equity | CN¥2.57b |
| Total liabilities | CN¥2.71b |
| Total assets | CN¥5.28b |
Recent financial health updates
Is Sirio Pharma (SZSE:300791) Using Too Much Debt?
Sep 23
Is Sirio Pharma (SZSE:300791) A Risky Investment?
Jun 12Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly
Mar 06Recent updates
When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?
Dec 13Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?
Oct 14The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More
Sep 30Is Sirio Pharma (SZSE:300791) Using Too Much Debt?
Sep 23Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares
Aug 01Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around
Jun 30Is Sirio Pharma (SZSE:300791) A Risky Investment?
Jun 12An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Apr 24Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly
Mar 06Financial Position Analysis
Short Term Liabilities: 300791's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥751.7M).
Long Term Liabilities: 300791's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥2.0B).
Debt to Equity History and Analysis
Debt Level: 300791's net debt to equity ratio (21.4%) is considered satisfactory.
Reducing Debt: 300791's debt to equity ratio has increased from 18% to 46.1% over the past 5 years.
Debt Coverage: 300791's debt is well covered by operating cash flow (31.7%).
Interest Coverage: 300791's interest payments on its debt are well covered by EBIT (4.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sirio Pharma Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Huang | Chasing Securities |
| Wenbo Chen | China International Capital Corporation Limited |
| Wendan Wang | China International Capital Corporation Limited |